1. Home
  2. GGRP vs INAB Comparison

GGRP vs INAB Comparison

Compare GGRP & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Glimpse Group Inc. Common Stock

GGRP

The Glimpse Group Inc. Common Stock

N/A

Current Price

$0.94

Market Cap

16.5M

Sector

Technology

ML Signal

N/A

Logo IN8bio Inc.

INAB

IN8bio Inc.

N/A

Current Price

$1.13

Market Cap

13.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GGRP
INAB
Founded
2016
2016
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
16.5M
13.7M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
GGRP
INAB
Price
$0.94
$1.13
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
96.1K
69.6K
Earning Date
05-15-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
65.79
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$72.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.42
$0.88
52 Week High
$1.08
$2.73

Technical Indicators

Market Signals
Indicator
GGRP
INAB
Relative Strength Index (RSI) 64.02 45.66
Support Level $0.73 N/A
Resistance Level $1.08 $1.50
Average True Range (ATR) 0.07 0.10
MACD 0.00 0.02
Stochastic Oscillator 81.55 66.73

Price Performance

Historical Comparison
GGRP
INAB

About GGRP The Glimpse Group Inc. Common Stock

The Glimpse Group Inc is a diversified immersive technology platform company, focused on providing enterprise solutions in virtual reality (VR), augmented reality (AR), and spatial computing. The company operates multiple subsidiaries that develop VR and AR software and services across various industries, including corporate training, education, healthcare, government, defense, marketing, retail, and financial services. It also offers AI-driven spatial computing platforms that support simulations, social VR, behavioral health, and corporate events. The Company reports its revenues in three categories: Software Services, Software License and Software-as-a-Service (SaaS), and Royalty Income, with the majority being from the Software Services category.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

Share on Social Networks: